Pharmaceutical giants Biocon Biologics has successfully completed the transition of its acquired biosimilars business in 120 countries across advanced and emerging markets, a year ahead of schedule, an official release stated on Monday.Over 10 .
The company said over 10 emerging markets along with Japan, Australia and New Zealand have transitioned in this final phase of the integration of the biosimilars business acquired from Viatris. With the completion of this significant milestone, Biocon Biologics is now a fully integrated ‘lab to market biosimilars company committed to serving millions of patients across the globe.
Earlier in 2023, over 70 Emerging Markets were integrated in July, the North American business transitioned in September and the European business in November, , Biocon Biologics
There has been a flurry of activity relating to proposed EYLEA® (aflibercept) biosimilars in November, starting with a BPCIA litigation against Celltrion’s proposed biosimilar CT-P42.